Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous KRAS G12D-specific HLA-C*08:02-restricted TCR gene engineered T lymphocytes NT-112

A preparation of autologous T lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-C*08:02-restricted oncogenic K-RAS (KRAS) substitution mutation G12D, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous KRAS G12D-specific HLA-C*08:02-restricted TCR gene engineered T lymphocytes NT-112 target and bind to KRAS G12D-expressing tumor cells, resulting in cytotoxic T-lymphocyte (CTL)-mediated killing of KRAS-G12D-expressing tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-KRAS G12D TCR-expressing T cells NT-112
autologous KRAS G12D-targeting TCR-T NT-112
Code name:NT 112
NT-112
NT112
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search